title: [Innovation of bisphosphonates for improvement of adherence.]
abstract: Bisphosphonates are standard medicine for treatment of osteoporosis, and have been inovated to overcome complicated rules for their appropriate administration or their poor intestinal absorption. Not only weekly but also monthly oral bisphosphonates have been available. Furthermore, we are now allowed to choose intravenous administration of bisphosphonates for osteorporosis. Good persistance and adherence is another critical and essential issue to be solved to achive the aim of osteoprosis treatment with bisphosphonates. Variable formulations of bisphosphonate are now able to bring patients closer to a goal of reduction in fragile fracture due to osteoporosis.
authors.affiliation: Endocrine Center, Toranomon Hospital, Tokyo, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Takeuchi
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D055118:Medication Adherence; D010024:Osteoporosis / Q000517:prevention & control*; D058866:Osteoporotic Fractures / Q000517:prevention & control*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates